Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

BACKGROUND: Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, and their large size may limit their tumor penetration, leading to suboptimal eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hao, Zhao, Zhen, Zhang, Li, Li, Yuanke, Jain, Akshay, Barve, Ashutosh, Jin, Wei, Liu, Yanli, Fetse, John, Cheng, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805442/
https://www.ncbi.nlm.nih.gov/pubmed/31640814
http://dx.doi.org/10.1186/s40425-019-0705-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805442/
https://www.ncbi.nlm.nih.gov/pubmed/31640814
http://dx.doi.org/10.1186/s40425-019-0705-y

Ejemplares similares